These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29253056)

  • 1. Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review.
    Spârchez Z; Mocan T
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):403-410. PubMed ID: 29253056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    Nagata H; Nakagawa M; Asahina Y; Sato A; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Nouchi T; Sakai H; Tomita M; Watanabe M;
    J Hepatol; 2017 Nov; 67(5):933-939. PubMed ID: 28627363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.
    Ishikawa T
    World J Gastroenterol; 2008 Oct; 14(40):6140-4. PubMed ID: 18985803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    Vukotic R; Di Donato R; Conti F; Scuteri A; Serra C; Andreone P
    J Viral Hepat; 2017 Jan; 24(1):13-16. PubMed ID: 27905669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis.
    Guarino M; Viganò L; Ponziani FR; Giannini EG; Lai Q; Morisco F;
    Dig Liver Dis; 2018 Nov; 50(11):1105-1114. PubMed ID: 30170908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals.
    Hernáez-Alsina T; Caballol-Oliva B; Díaz-González Á; Guedes-Leal C; Reig M
    Gastroenterol Hepatol; 2019 Oct; 42(8):502-511. PubMed ID: 31472990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
    Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.
    Omata M; Yoshida H; Shiratori Y
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S141-3. PubMed ID: 16234063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
    Masuzaki R; Yoshida H; Omata M
    Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].
    Lengyel G; Fehér J
    Orv Hetil; 2010 Jul; 151(29):1177-81. PubMed ID: 20591786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of interferon-based therapy for chronic hepatitis C.
    Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
    Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.
    Li DK; Chung RT
    Cancer; 2015 Sep; 121(17):2874-82. PubMed ID: 26079399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.
    Villani R; Vendemiale G; Serviddio G
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?
    Hsu SJ; Yang SS; Kao JH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):3-11. PubMed ID: 31627984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.